

UCSF Clinical and Translational Science Institute
2014
Annual Retreat
Agenda

12:00-12:30pm	Lunch
12:30-12:55	Update on Overall Plans for the CTSI Proposal (Deborah Grady)
12:55-1:00	Today's Agenda (Alice Fishman) Introduction of Hal Barron, MD, FACC (June Lee)
1:00-1:30	Translational Research: The Power of Bedside to Bench Dr. Barron (President of Research and Development, Calico)
1:30-1:40	Q & A with Dr. Barron
1:40-1:50	Instructions for Small Group Discussion (Alice Fishman)
1:50-2:50	Small Group Discussion a) What are the major strengths and weaknesses of this program proposal? b) How can it be strengthened to maximize impact? c) What foundation exists on campus already that will ensure success of the program proposal? d) What creative and/or innovative partnerships could be leveraged to ensure success?
2:50-3:20	Break
3:20-4:20	Small Group Report-Outs
4:20-4:45	Summary and Next Steps (Deborah Grady)
4:45-5:00	CTSI Awards (Deborah Grady)
5:00	Retreat Close
5:00-6:00	Reception

Please join the conversation on Twitter at #CTSI2014

BIOSKETCH

Hal V. Barron, MD FACC

President, Research and Development; Calico Life Sciences

Associate Adjunct Professor of Epidemiology and Biostatistics
University of California, San Francisco

Member, Board of Directors; Genentech Inc.

Dr. Barron is an internationally recognized clinical and translational physician-scientist as well as pharmaceutical executive. He joined Genentech in 1996 as a clinical scientist. During the next several years, he held positions of increasing responsibility and leadership within the Cardiovascular Research and Specialty Therapeutics Division. In 2002, Dr. Barron was promoted to Vice President, Medical Affairs for Genentech. In 2003 he became the Senior Vice President of Development and in 2004 he was appointed Chief Medical Officer. In 2010, when Roche acquired Genentech, he was appointed the Executive Vice President, Head of Global Product Development and Chief Medical Officer for the new combined entity.

In this capacity, Dr. Barron oversaw the development of numerous new medicines and was very involved in developing and assessing the predictive and prognostic value of numerous biomarkers. These included companion (predictive) diagnostics such as Her2, EGFR, BRAF and several others that are still in development for diseases outside of oncology such as dry Age-related Macular Degeneration, Inflammatory Bowel Disease, and Asthma. In addition, he has extensive experience with both developing and assessing pharmacodynamic biomarkers as well as surrogate markers for assessing drug activity in patients.

With his recent move to become head of Research and Development at Calico, a company focused on understanding the cellular and molecular basis of aging, Dr. Barron will be overseeing a team of researchers and clinicians with the ultimate goal of developing new therapeutics to extend life and healthy living. One avenue of exploration will be to assess the utility of biomarkers of biologic age.

Prior to joining Industry, Dr. Barron received his Bachelor of Science in physics from Washington University in St. Louis, his Medical Degree from Yale University and completed his training in medicine and cardiology at the University of California San Francisco.

Please join the conversation on Twitter at #CTSI2014